Analystreport

Marker Therapeutics (NASDAQ:MRKR) had its "buy" rating reaffirmed by analysts at UBS Group AG.

Marker Therapeutics, Inc.  (MRKR) 
Last marker therapeutics, inc. earnings: 11/12 04:01 pm Check Earnings Report